A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

Journal of the American College of Cardiology

Volumn 23, Issue 5, 1994, Pages 993-1003

  Cannon, Christopher P ^a   McCabe, Carolyn H ^a   Henry, Timothy D ^a   Schweiger, Marc J ^b   Gibson, Robert S ^c   Mueller, Hiltrud S ^d   Becker, Richard C ^e   Kleiman, Neal S ^f   Haugland, J Mark ^a   Anderson, Jeffrey L ^g   Sharaf, Barry L ^h   Edwards, Susan J ⁱ   Rogers, William J ^j   Williams, David O ^h   Braunwald, Eugene ^k  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CGS 39393; DESULFATOHIRUDIN; HEPARIN; HIRUDIN DERIVATIVE; METOPROLOL; METOPROLOL TARTRATE; RECOMBINANT DESULFATOHIRUDIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, PHARMACEUTIC; ADULT; AGED; ASPIRIN; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; RECOMBINANT PROTEINS; SURVIVAL RATE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0028296374     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(94)90581-9     Document Type: Article

References (50)

1. The Thrombolysis in Myocardial Infarction (TIMI) trial; Phase I findings
2. Enhancing thrombolytic efficacy by means of “front-loaded” administration of tissue plasminogen activator
3. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? [abstract]
4. GUSTO, TIMI and the case for rapid reperfusion
5. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
6. Prognostic significance of nonfatal reinfarction in TIMI II [abstract]
7. Pathogenesis of thrombosis
8. Hirudin, heparin and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis
9. Relative efficacy of antithrombin compared with antiplatetet agents in accelerating coronary thrombolysis and preventing reocclusion
10. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion
11. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy
12. Pharmacokinetics and anticoagulant effect of hirudin in man
13. Biology of recombinant hirudin (CGP 39393) a new prospect in the treatment of thrombosis
14. The structure of a complex of recombinant hirudin and human alpha-thrombin
15. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor
16. Heparin
17. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
18. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial
19. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase
20. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator heparin and aspirin for acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial
21. Evidence of a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
22. Reactivation of unstable angina after the discontinuation of heparin
23. Thrombolytic therapy with tissuc-plasminogen activator or streptokinase induces transient thrombin activity
24. Paradoxical elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis
25. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
26. Does Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 Study
27. Relationsbip of coronary flow to myocardial infarction size: two simple new methods to subclassify TIMI flow grades [abstract]
28. Is a coronary artery with TIMI grade 2 flow “patent”? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial [abstract]
29. Consequences of TIMI 2 vs 3 flow at 90 minutes following thrombolysis [abstract]
30. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic and electrocardiographic evidence from the TEAM-3 Study
31. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies
32. The comparative effects of tissue plasminogen activator streptokinase or both on coronary artery patency ventricular function and survival after acute myocardial infarction
33. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
34. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA)
35. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded?
36. Six- and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) trial
37. Prognosis after acute myocardial infarction in patients with and without residua antegrade coronary blood flow
38. Risk stratification for 1 year: jurvival based on characteristics identified in the early hours of acute myocardial infarction
39. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of Thrombolysis and Angioplasty in Myocardial Infarction—Phase 5 randomized trial
40. The quest for the ideal reperfusion strategy continues
41. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction TIMI II A results
42. A randomizedtrial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
43. Early infarct artery patency after intravenous streptokinase intracoronary contrast and intracoronary rt-PA [abstract]
44. Kinetics of the inhibition of thrombin by hirudin
45. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis
46. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
47. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relationship to coronary artery patency
48. Relationship of coagulation parameters to patency at 18–48 hours in the Thrombolysis in Myocardial Infarction Phase II trial [abstract]
49. Some objective considerations for the neutralization of the anticoagulant effects of recombinant hirudin